Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 11,338 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Epilepsies, Myoclonic, Drug Resistant Epilepsy
Interventions: Lorcaserin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Urothelial Carcinoma
Interventions: Zilovertamab vedotin, Pembrolizumab, MK-3120; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 10
States / cities: Orange, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Ovarian Cancer
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 31
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Amyloidosis
Interventions: Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg, Daratumumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Duarte, California • San Francisco, California + 22 more

Conditions: Automated Measurement of Vital Signs
Interventions: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration, Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration; Device
Lead sponsor: LifeWatch Services, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 16
States / cities: Cedar Rapids, Iowa • Kalamazoo, Michigan • East Orange, New Jersey + 10 more

Conditions: Chronic Low-Back Pain, Refractory Pain, Neuropathic Pain
Interventions: Spinal Cord Stimulation, Conventional Medical Management; Device · Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Camarillo, California + 27 more

Conditions: Sleep Apnea, Atrial Fibrillation
Interventions: Continuous Positive Airway Pressure; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza A, Influenza B
Interventions: Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more

Conditions: Hot Flashes
Interventions: Gabapentin Extended Release, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more

Conditions: Type 1 Diabetes
Interventions: Insulin Pump with Continuous Glucose Monitoring; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 5 more

Conditions: Colonic Diseases, Rectal Diseases
Interventions: Bipolar electrosurgical generator and instruments, Disposable stapling instruments; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 431
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more

Conditions: Dry Eye Syndromes
Interventions: AGN-195263, Vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 29
States / cities: Chandler, Arizona • Fullerton, California • Garden Grove, California + 26 more

Conditions: Cardiac Arrest
Interventions: Therapeutic Hypothermia, Therapeutic Normothermia; Procedure · Other
Lead sponsor: University of Michigan; Other
Eligibility: 48 Hours to 18 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 136
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more

Conditions: Psoriasis
Interventions: CTA018 cream; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more

Conditions: Atrial Fibrillation
Interventions: WATCHMAN FLX Implant, Market-approved OAC; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 70 more

Conditions: Small Cell Lung Cancer
Interventions: Alisertib, Placebo, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more

Conditions: Lung Cancer
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Detroit, Michigan • Cleveland, Ohio

Conditions: Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: Unity Health Toronto; Other
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more

Conditions: Arthritis, Rheumatoid, Crohn Disease, Psoriasis
Interventions: Infliximab (Remicade); Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 100
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Celecoxib; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 67
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 58 more

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Patient Reported Symptoms in Ovarian Cancer (PRECISION)

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Vital Signs Patch: Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)

Influence of Sleep Apnea on Risk of Atrial Fibrillation

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children

Random Comparison of LigaSure and Disposable Staples for Laparoscopic Surgery

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

A Long-term Safety Study of Infliximab (Remicade)

Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"